menu search

Are ozempic and similar treatments impacting food and beverage stocks? here's what pepsi's cfo said about it

Pepsi's CFO addressed the impacts of Ozempic and its sister treatments on the overall business. These c...

October 14, 2023, 8:03 am

Relmada and rel-1017: intriguing underlying efficacy in mdd ahead of eventful 2024

Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying eff...

October 13, 2023, 7:50 pm

Mind medicine: q4 of 2023 data for gad makes this worth a look

Results from the phase 2b study, using MM-120 for the treatment of patients with generalized anxiety di...

October 13, 2023, 6:37 pm

Pfizer slashes full-year earnings and revenue guidance as covid treatment, vaccine sales slump

Pfizer said it anticipates sales of its Covid treatment Paxlovid and its vaccine will be $9 billion les...

October 13, 2023, 5:47 pm

Novo nordisk boosts its guidance on demand for its weight-loss drugs, again

Novo Nordisk (NVO) boosted its guidance for the second time in two months as demand soars for its diabetes tre...

October 13, 2023, 5:05 pm

Cidara therapeutics and mundipharma receive positive chmp opinion for rezafungin for the treatment of invasive candidiasis in adults(1)

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and e...

October 13, 2023, 2:34 pm

: sanofi reaps rewards of immunology investment with eczema results

Pharmaceutical giant set to take on Amgen with atopic dermatitis treatment. Read Full Story The post : ...

October 13, 2023, 2:00 pm

Sewage submersible pump market to exceed usd 16.8 billion in 2031, rising at a cagr of 5.3% – exclusive report by transparency market research

The increase in the number of households increases the production of domestic sewage, boosting the demand for wastewater ...

October 13, 2023, 1:30 pm

Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...

October 13, 2023, 12:38 pm

Intellia therapeutics receives priority medicines (prime) designation from the european medicines agency for ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioe

CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focuse...

October 13, 2023, 12:38 pm

: amylyx pharmaceuticals shares fall after als treatment is rejected by european regulator

Amylyx Pharmaceuticals Inc. AMLX shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its negative ...

October 13, 2023, 12:31 pm

Harmony biosciences stock drops on disappointing study results

Harmony Biosciences Holdings Inc shares sank 38% to $18.66 in late-morning trading on Friday after the pharmaceutical company reported topline results...

October 13, 2023, 11:29 am

Unitedhealth to work on making newer diabetes drugs more affordable

UnitedHealth Group said on Friday it will focus on finding a way to make GLP-1 drugs, used for the treatment...

October 13, 2023, 9:51 am

Alpine immune sciences to present initial clinical data on povetacicept in autoimmune glomerulonephritis in a late breaker poster session at american society of nephrology kidney week 2023

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative...

October 13, 2023, 9:05 am

Amylyx pharmaceuticals shares fall after als treatment is rejected by european regulator

Amylyx Pharmaceuticals Inc. AMLX, -4.60% shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its n...

October 13, 2023, 8:31 am

Abbvie's (abbv) rinvoq meets key goal in phase ii vitiligo study

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult ...

October 13, 2023, 8:16 am

Why scholar rock holding stock soared today

Scholar Rock announced it will advance the development of its obesity treatment, SRK-439, starting with...

October 12, 2023, 4:17 pm

Leukemia therapeutics treatment market set to achieve us$ 30,318.5 million by 2033 at 7.1% cagr | future market insights inc.

Innovations in leukemia treatment require substantial investments, and larger companies with robust fin...

October 12, 2023, 3:30 pm


Search within

Pages Search Results: